Rate Video

EHA 2015 | ELOQUENT-2 trial of elotuzumab plus lenalidomide/dexamethasone in multiple myeloma

Sagar Lonial • 2 Jun 2015

EHA 2015

Multiple Myeloma Antibodies Elotuzumab

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, discusses the results of the randomized, open-label, phase 3 ELOQUENT-2 trial of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or refractory multiple myeloma.

DARA + pom-dex for R/R multiple myeloma

Impact of prior therapies on efficacy of belantamab mafodotin in R/R myeloma

Sagar Lonial • 19 Jun 2020

BCMA-targeting CAR-T: lessons moving forward

Sagar Lonial • 17 May 2019

Rise of antibody-based treatments in myeloma

Sagar Lonial • 2 Sep 2020

Related Videos

A.R.R.O.W. study: carfilzomib dosing in frail MM patients

Maria-Victoria Mateos

Managing CRS in myeloma

Managing transplant patients during the COVID-19 pandemic

Christian Chabannon

DNA methyltransferase inhibitors: daratumumab enhancement for MM